Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion : a PK/PD simulation study
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: The new definitions of antimicrobial susceptibility categories proposed by EUCAST in 2020 require the definition of standard and high dosages of antibiotic. For injectable β-lactams, standard and high dosages have been proposed for short-infusion regimens only.
OBJECTIVES: To evaluate dosages for β-lactams administered by prolonged infusion (PI) and continuous infusion (CI).
METHODS: Monte Carlo simulations were performed for seven injectable β-lactams: aztreonam, cefepime, cefotaxime, cefoxitin, ceftazidime, piperacillin and temocillin. Various dosage regimens based on short infusion, PI or CI were simulated in virtual patients. Pharmacokinetic (PK) profiles and PTAs were obtained based on reference population PK models, as well as PK/pharmacodynamic targets and MIC breakpoints proposed by EUCAST. Alternative dosage regimens associated with PTA values similar to those of recommended dosages up to the breakpoints were considered acceptable.
RESULTS: Adequate PTAs were confirmed for most EUCAST short-infusion dosage regimens. A total of 9 standard and 14 high dosages based on PI (3 to 4 h) or CI were identified as alternatives. For cefepime and aztreonam, only PI and CI regimens could achieve acceptable PTAs for infections caused by Pseudomonas spp.: 2 g q8h as PI of 4 h or 6 g/24 h CI for cefepime; 2 g q6h as PI of 3 h or 6 g/24 h CI for aztreonam.
CONCLUSIONS: These alternative standard and high dosage regimens are expected to provide antibiotic exposure compatible with new EUCAST definitions of susceptibility categories and associated MIC breakpoints. However, further clinical evaluation is necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 78(2023), 11 vom: 06. Nov., Seite 2762-2769 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goutelle, Sylvain [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
807PW4VQE3 |
|---|
| Anmerkungen: |
Date Completed 10.11.2023 Date Revised 11.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad300 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362906777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362906777 | ||
| 003 | DE-627 | ||
| 005 | 20231226092223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad300 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362906777 | ||
| 035 | |a (NLM)37796958 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goutelle, Sylvain |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion |b a PK/PD simulation study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.11.2023 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The new definitions of antimicrobial susceptibility categories proposed by EUCAST in 2020 require the definition of standard and high dosages of antibiotic. For injectable β-lactams, standard and high dosages have been proposed for short-infusion regimens only | ||
| 520 | |a OBJECTIVES: To evaluate dosages for β-lactams administered by prolonged infusion (PI) and continuous infusion (CI) | ||
| 520 | |a METHODS: Monte Carlo simulations were performed for seven injectable β-lactams: aztreonam, cefepime, cefotaxime, cefoxitin, ceftazidime, piperacillin and temocillin. Various dosage regimens based on short infusion, PI or CI were simulated in virtual patients. Pharmacokinetic (PK) profiles and PTAs were obtained based on reference population PK models, as well as PK/pharmacodynamic targets and MIC breakpoints proposed by EUCAST. Alternative dosage regimens associated with PTA values similar to those of recommended dosages up to the breakpoints were considered acceptable | ||
| 520 | |a RESULTS: Adequate PTAs were confirmed for most EUCAST short-infusion dosage regimens. A total of 9 standard and 14 high dosages based on PI (3 to 4 h) or CI were identified as alternatives. For cefepime and aztreonam, only PI and CI regimens could achieve acceptable PTAs for infections caused by Pseudomonas spp.: 2 g q8h as PI of 4 h or 6 g/24 h CI for cefepime; 2 g q6h as PI of 3 h or 6 g/24 h CI for aztreonam | ||
| 520 | |a CONCLUSIONS: These alternative standard and high dosage regimens are expected to provide antibiotic exposure compatible with new EUCAST definitions of susceptibility categories and associated MIC breakpoints. However, further clinical evaluation is necessary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cefepime |2 NLM | |
| 650 | 7 | |a 807PW4VQE3 |2 NLM | |
| 650 | 7 | |a Aztreonam |2 NLM | |
| 650 | 7 | |a G2B4VE5GH8 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Ceftazidime |2 NLM | |
| 650 | 7 | |a 9M416Z9QNR |2 NLM | |
| 650 | 7 | |a Piperacillin |2 NLM | |
| 650 | 7 | |a X00B0D5O0E |2 NLM | |
| 700 | 1 | |a Jullien, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Bru, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Cattoir, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Gauzit, Rémy |e verfasserin |4 aut | |
| 700 | 1 | |a Lesprit, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Lina, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Schramm, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Canoui, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Lepeule, Raphael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 78(2023), 11 vom: 06. Nov., Seite 2762-2769 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:11 |g day:06 |g month:11 |g pages:2762-2769 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad300 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 11 |b 06 |c 11 |h 2762-2769 | ||